Malignant Melanoma
📧 Sign up to get email alerts when something new happens for Malignant Melanoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2019-01-25Clinical Trial Update: Melanoma Image Analysis Algorithm (MIAA) Validation Study [NA]
Completed validation study of the Melanoma Image Analysis Algorithm (MIAA) developed by Skin Analytics Limited for malignant melanoma.
-
CLINICAL_TRIALS trial_result · 2019-01-23Clinical Trial Update: Dabrafenib and Trametinib for BRAF-inhibitor Pretreated Patients [Phase 2]
This update summarizes the completed Phase 2 trial of dabrafenib and trametinib in malignant melanoma patients who were pretreated with BRAF…
-
CLINICAL_TRIALS trial_result · 2018-12-27Clinical Trial Update: Study to Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors [Phase 1, Phase 2]
A pediatric Phase 1/2 study assessed the safety and early activity of weekly nab-paclitaxel in children with recurrent or refractory solid t…
-
CLINICAL_TRIALS trial_result · 2018-09-26Clinical Trial Update: A Study of Combination Treatment With HF10 and Ipilimumab in Patients With Unresectable or Metastatic Melanoma [Phase 2]
Phase 2 trial update evaluating a combination of HF10 with ipilimumab in unresectable or metastatic malignant melanoma; study completed.
-
FDA approval · 2018-06-27FDA Approved: BRAFTOVI — Original Application (Array BioPharma Inc.)
FDA approved BRAFTOVI (encorafenib) under the original application (NDA210496) from Array BioPharma Inc., marking the drug's initial approva…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2018-06-19Clinical Trial Update: An Observational Safety Study in Zelboraf (Vemurafenib)-Treated Patients With BRAF-V600 Mutation-Positive Unresectable or Metastatic Melanoma (ZeSS)
This entry reports the completion of an observational safety study of vemurafenib (Zelboraf) in patients with BRAF V600 mutation-positive un…
-
CLINICAL_TRIALS trial_result · 2018-05-01Clinical Trial Update: Bevacizumab and Temozolomide or Bevacizumab and Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed by Surgery [Phase 2]
This Phase 2 trial evaluated bevacizumab with temozolomide or bevacizumab with nab-paclitaxel and carboplatin in patients with stage IV mali…
-
CLINICAL_TRIALS trial_result · 2018-04-23Clinical Trial Update: CAVATAK in Patients With Stage IIIc or IV Malignant Melanoma to Extend Dosing to 48 Weeks (VLA-008 CALM Ext) [Phase 2]
A Phase 2 trial investigating extended dosing of CAVATAK in patients with advanced melanoma (Stage IIIc/IV) has completed and posted results…
-
FDA approval · 2018-01-26FDA Approved: COTELLIC — Supplemental Application (Genentech, Inc.)
FDA approved a supplemental application for COTELLIC (cobimetinib) from Genentech, Inc.
-
CLINICAL_TRIALS trial_result · 2017-12-27Clinical Trial Update: Clinical Study of Apatinib as the Second-line Therapy in Malignant Melanoma [Phase 2]
Phase 2 clinical study investigating apatinib as second-line therapy for malignant melanoma.
-
CLINICAL_TRIALS trial_result · 2017-12-20Clinical Trial Update: Fluorescein for Lymphatic Mapping and Sentinel Lymph Node (SLN) Biopsy in Patients With Stage I and II Malignant Melanoma [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluating fluorescein for lymphatic mapping and sentinel lymph node biopsy in patients with stage I-II malignant…
-
CLINICAL_TRIALS trial_result · 2017-12-18Clinical Trial Update: A Study of Vemurafenib in Participants With Metastatic Melanoma [Phase 3]
Phase 3 trial update for vemurafenib in metastatic melanoma has completed; results posted.
-
CLINICAL_TRIALS trial_result · 2017-11-14Clinical Trial Update: Bioavailability Study of Vemurafenib in Participants With BRAF^V600 Mutation-Positive Malignancies [Phase 1]
Phase 1 bioavailability study of vemurafenib in participants with BRAF V600 mutation-positive malignancies has completed.
-
CLINICAL_TRIALS trial_result · 2017-10-03Clinical Trial Update: Combination of Decitabine and Temozolomide in the Treatment of Patients With Metastatic Melanoma [Phase 1, Phase 2]
Clinical trial update on the combination of Decitabine and Temozolomide in metastatic melanoma (Phase 1/2) with completed status and posted …
-
CLINICAL_TRIALS trial_result · 2017-08-24Clinical Trial Update: Selective HDAC6 Inhibitor ACY-241 in Combination With Ipilimumab and Nivolumab [Phase 1]
Phase 1 study evaluating the selective HDAC6 inhibitor ACY-241 in combination with ipilimumab and nivolumab for malignant melanoma has compl…
-
CLINICAL_TRIALS trial_result · 2017-08-22Clinical Trial Update: Safety Study of PLX4032 in Patients With Solid Tumors [Phase 1]
Phase 1 safety study of PLX4032 (vemurafenib) in patients with solid tumors, including malignant melanoma and colorectal cancer; results hav…
-
CLINICAL_TRIALS trial_result · 2017-06-09Clinical Trial Update: Temsirolimus and Bevacizumab in Treating Patients With Stage III or Stage IV Malignant Melanoma [Phase 2]
This is a Phase 2 trial evaluating temsirolimus in combination with bevacizumab for stage III/IV malignant melanoma; results have been poste…
-
CLINICAL_TRIALS trial_result · 2017-06-09Clinical Trial Update: In Vitro Expanded Autologous Invariant Natural Killer Cells in Cancer [Phase 1]
A Phase 1 trial evaluated autologous invariant natural killer (iNKT) cells expanded in vitro for cancer therapy in malignant melanoma and ha…
-
CLINICAL_TRIALS trial_result · 2017-05-25Clinical Trial Update: Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E [Phase 2]
Phase 2 study of vemurafenib (Zelboraf) in patients with locally advanced unresectable Stage IIIc or metastatic melanoma carrying activating…
-
CLINICAL_TRIALS trial_result · 2017-05-15Clinical Trial Update: A Study of Intratumoral CAVATAK™ in Patients With Stage IIIc and Stage IV Malignant Melanoma (VLA-007 CALM ) [Phase 2]
Phase 2 study of intratumoral CAVATAK in patients with stage IIIc/IV malignant melanoma has completed; results posted in 2017.
-
CLINICAL_TRIALS trial_result · 2017-05-03Clinical Trial Update: Pegylated Interferon-alpha-2a in Patients With Malignant Melanoma Stage IIA-IIIB [Phase 3]
A Phase 3 clinical trial evaluating Pegylated Interferon-alpha-2a in patients with malignant melanoma (Stage IIA-IIIB) has completed.
-
CLINICAL_TRIALS trial_result · 2017-04-21Clinical Trial Update: A Study of Bevacizumab (Avastin) in Combination With Dacarbazine in Participants With Unresectable/Metastatic Melanoma [Phase 2]
Phase 2 trial evaluating bevacizumab in combination with dacarbazine in unresectable/metastatic melanoma has completed and results have been…
-
CLINICAL_TRIALS trial_result · 2017-04-19Clinical Trial Update: A Phase II Study of Vemurafenib Combined With Acitretin in Patients With Advanced Melanoma [Phase 2]
Phase II trial evaluating vemurafenib combined with acitretin in advanced melanoma has been terminated; results posted.
-
CLINICAL_TRIALS trial_result · 2017-03-28Clinical Trial Update: Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Participants With Advanced Melanoma (MK-3475-002/P08719/KEYNOTE-002) [Phase 2]
A Phase 2 trial comparing pembrolizumab to chemotherapy in advanced melanoma has completed with results posted in 2017.
-
CLINICAL_TRIALS trial_result · 2017-03-22Clinical Trial Update: A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037) [Phase 3]
Phase 3 trial comparing BMS-936558 (nivolumab) to physician's choice chemotherapy in advanced melanoma after anti-CTLA-4 therapy; trial comp…